Ang (1-7) derivative oligopeptides and methods for using and producing the same
AssigneeArizona Board of Regents on Behalf of the University of Arizona
InventorsMeredith Hay, John Konhilas, Robin L. Polt, Evan Jones, Lajos Szabo
Life of this patent
Estimating the term…
Abstract
The present invention provides oligopeptides, in particular, Ang-(1-7) derivatives, and methods for using and producing the same. In one particular embodiment, oligopeptides of the invention have higher blood-brain barrier penetration and/or in vivo half-life compared to the native Ang-(1-7), thereby allowing oligopeptides of the invention to be used in a wide variety of clinical applications including in treatment of cognitive dysfunction and/of impairment.
Claims16
A method for treating conditions associated with an increase in inflammatory cytokines and/or increase in reactive oxygen species that can cause cognitive dysfunction and/or impairment in a subject comprising systemically administering to the subject a therapeutically effective amount of a heptapeptide having the formula:
- A1-A2-A3-A4-A5-A6-A7-A8 (SEQ ID NO:1) wherein A1 is selected from the group consisting of aspartic acid, glutamic acid, alanine, and glycosylated forms thereof;
- A2 is selected from the group consisting of arginine, histidine, lysine, and glycosylated forms thereof;
- A3 is selected from the group consisting of valine, alanine, isoleucine, leucine, and glycosylated forms thereof;
- A4 is selected from the group consisting of tyrosine, phenylalanine, tryptophan, and glycosylated forms thereof;
- A5 is selected from the group consisting of isoleucine, valine, alanine, leucine, and glycosylated forms thereof;
- A6 is selected from the group consisting of histidine, arginine, lysine, and glycosylated forms thereof;
- A7 is serine or a glycosylated form thereof;
- and A8 is absent.
A method for treating conditions associated with an increase in inflammatory cytokines and/or increase in reactive oxygen species that can cause cognitive dysfunction and/or impairment in a subject comprising systemically administering to the subject a therapeutically effective amount of an octapeptide having the formula:
- A1-A2-A3-A4-A5-A6-A7-A8 (SEQ ID NO:
- 1) wherein A1 is selected from the group consisting of aspartic acid, glutamic acid, alanine, and glycosylated forms thereof;
- A2 is selected from the group consisting of arginine, histidine, lysine, and glycosylated forms thereof;
- A3 is selected from the group consisting of valine, alanine, isoleucine, leucine, and glycosylated forms thereof;
- A4 is selected from the group consisting of tyrosine, phenylalanine, tryptophan, and glycosylated forms thereof;
- A5 is selected from the group consisting of isoleucine, valine, alanine, leucine, and glycosylated forms thereof;
- A6 is selected from the group consisting of histidine, arginine, lysine, and glycosylated forms thereof;
- A7 is selected from the group consisting of proline, glycine, serine, and glycosylated forms thereof;
- and A8 is selected from the group consisting of serine, threonine, hydroxyproline, and glycosylated forms thereof, and wherein at least one of A1-A8 is glycosylated.
Dependencies are inferred from the claim text.